CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Pantoprazole +2 moredrug
Likely dose
Pantoprazole 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674245
NCT00674245Phase 3Completed
CompareCT.gov

The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD)

Southern Arizona VA Health Care System·interventional·Posted May 7, 2008·Updated Aug 19, 2010

In Brief

A Phase 3 clinical trial evaluating Pantoprazole and placebo for Gastroesophageal Reflux Disease. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.2 years ago

Interventions

Pantoprazoledrug

40 mg once daily for 4 weeks

Pantoprazoledrug

40 mg once daily improves sleep quality in patients with GERD.

placebodrug

40 mg once daily for 4 weeks